Cardio Diagnostics Holdings Inc.

10/15/2025 | Press release | Distributed by Public on 10/15/2025 14:45

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On October 15, 2025, Cardio Diagnostics Holdings, Inc., a Delaware corporation (the "Company") held its annual meeting of stockholders (the "Annual Meeting"). Of the Company's 1,763,129 shares of common stock issued and outstanding and eligible to vote as of the record date of August 25, 2025, a total of 927,526 shares, or approximately 52.6% of the eligible shares, was in attendance or represented by proxy. The Company's stockholders voted on three proposals as set forth below. Each of the proposals is described in further detail in the Company's definitive proxy statement, which was filed with the Securities and Exchange Commission on September 4, 2025. The final voting results, including the number of votes cast for, against, or withholding authority, and the number of abstentions and any broker non-votes, with respect to each matter voted upon are set forth below, as reported by the Company's independent inspector of election.

Proposal 1: Election of Directors (the "Election of Directors Proposal")

The Company's stockholders elected seven directors to serve for the ensuing year and until their successors are elected and qualified, or until their earlier death, resignation or removal. The Company elects its directors on a plurality vote basis. The votes regarding the election of directors were as follows:

Nominee For Authority Withheld Broker Non-Votes
Meeshanthini V. Dogan 361,246 103,733 462,547
Warren Hosseinion 429,765 35,214 462,547
Wendy J. Betts 355,919 109,060 462,547
Paul F. Burton 428,090 36,889 462,547
Peter K. Fung 433,252 31,727 462,547
James Intrater 427,266 37,713 462,547
Robert Philibert 431,160 33,819 462,547

Proposal 2: Approval of the future issuance of shares of Common Stock and/or securities convertible into or exercisable for Common Stock equal to 20% or more of the Common Stock outstanding in one or more non-public transactions as required by Nasdaq Marketplace Listing Rule 5635(d) (the "Share Issuance Proposal")

The Share Issuance Proposal was approved. Any non-public financing transaction undertaken in connection with this approval will be conducted within the parameters set forth in the Share Issuance Proposal described in the proxy statement for the Annual Meeting.

For Against Abstain Broker Non-Votes
283,304 166,492 15,183 462,547

Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm (the "Auditor Ratification Proposal")

The ratification of the appointment of Prager Metis CPA's LLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved.

For Against Abstain
813,401 64,820 49,305
Cardio Diagnostics Holdings Inc. published this content on October 15, 2025, and is solely responsible for the information contained herein. Distributed via EDGAR on October 15, 2025 at 20:46 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]